Reps, Jenna Marie
Williams, Ross D.
Schuemie, Martijn J.
Ryan, Patrick B.
Rijnbeek, Peter R.
Funding for this research was provided by:
Innovative Medicines Initiative (806968, 806968)
Article History
Received: 30 December 2021
Accepted: 13 May 2022
First Online: 25 May 2022
Declarations
:
: All patient data included in this study were deidentified. The New England Institutional Review Board determined that studies conducted in Optum/IBM data are exempt from study-specific IRB review, as these studies do not qualify as human subjects research. No experiments were conducted on humans in this study. The research methods were conducted in accordance with appropriate guidelines.
: Not applicable.
: JMR, MJS, PBR are employees of Janssen Research and Development and shareholders of Johnson and Johnson. PRR and RDW work for a research group who received unconditional research grants from Boehringer-Ingelheim, GSK, Janssen Research & Development, Novartis, Pfizer, Yamanouchi, Servier. None of these grants result in a conflict of interest to the content of this paper.